Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anterior Interosseous Nerve to Ulnar Nerve Transfer: A Systematic Review.

JPRAS open·2022
Same author

Thromboelastography in Microsurgical Reconstruction: A Systematic Review.

JPRAS open·2022
Same author

Re: "Hyperbaric Oxygen therapy for large composite grafts: An alternative in pediatric facial reconstruction".

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2021
Same author

Response to "Re: Should WALANT surgery be included in the training curriculum?"

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2021
Same author

Braided absorbable sutures for traumatic wounds.

JPRAS open·2021
Same author

WALANT and sickle cell disease: A cautionary tale.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2021

Related Experiment Video

Updated: Jul 7, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

ST 567 compared with propranolol in stable angina.

L Ceremuzynski1, E Nartowicz, M Dluzniewski

  • 1Department Cardiology, Warsaw Postgraduate Medical School, Poland.

European Heart Journal
|December 1, 1987
PubMed
Summary

ST 567 effectively treats chronic angina by reducing heart rate and anginal attacks. However, propranolol demonstrated slightly superior efficacy in the studied dosages for ischemic heart disease patients.

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Related Experiment Videos

Last Updated: Jul 7, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ischemic heart disease (IHD) and angina pectoris significantly impact patient quality of life.
  • Effective management of IHD symptoms is crucial for preventing adverse cardiac events.

Purpose of the Study:

  • To evaluate the efficacy of ST 567 in patients with stable, exercise-induced angina pectoris.
  • To compare the therapeutic effects of ST 567 with propranolol, a standard beta-blocker, in IHD patients.

Main Methods:

  • A double-blind, randomized study involving 48 male patients with stable angina.
  • Patients received either ST 567 (3 x 30 mg) or propranolol (3 x 40 mg) for four weeks after a placebo run-in period.

Main Results:

  • Both ST 567 and propranolol significantly reduced resting heart rate and anginal attacks.
  • ST 567 increased exercise tolerance and decreased nitroglycerin use, though propranolol showed slightly greater improvements.
  • ST 567 had a higher dropout rate due to adverse events like myocardial infarction and visual disturbances.

Conclusions:

  • ST 567 is an effective treatment for chronic angina.
  • Propranolol demonstrated slightly superior efficacy and a better safety profile compared to ST 567 at the studied dosages for ischemic heart disease.